Repligen Corporation (NASDAQ:RGEN) was upgraded by equities researchers at TheStreet from a “c+” rating to a “b-” rating in a research note issued to investors on Friday.

Other equities analysts also recently issued reports about the stock. Janney Montgomery Scott increased their price target on shares of Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Zacks Investment Research downgraded shares of Repligen Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, June 6th. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. Finally, William Blair initiated coverage on shares of Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $42.00.

Shares of Repligen Corporation (NASDAQ RGEN) opened at 41.61 on Friday. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of 81.43 and a beta of 1.30. The company has a 50-day moving average price of $41.83 and a 200-day moving average price of $36.83. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The company had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. During the same period in the prior year, the firm earned $0.16 earnings per share. Repligen Corporation’s revenue was up 11.0% on a year-over-year basis. On average, equities analysts anticipate that Repligen Corporation will post $0.59 EPS for the current year.

WARNING: “Repligen Corporation (RGEN) Upgraded to B- by TheStreet” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/repligen-corporation-rgen-upgraded-to-b-by-thestreet/1489612.html.

Several institutional investors have recently made changes to their positions in RGEN. BlackRock Inc. increased its position in shares of Repligen Corporation by 143,196.5% in the first quarter. BlackRock Inc. now owns 4,664,302 shares of the biotechnology company’s stock worth $164,187,000 after buying an additional 4,661,047 shares in the last quarter. TimesSquare Capital Management LLC increased its position in shares of Repligen Corporation by 35.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,970,725 shares of the biotechnology company’s stock worth $69,370,000 after buying an additional 512,300 shares in the last quarter. William Blair Investment Management LLC increased its position in shares of Repligen Corporation by 49.8% in the second quarter. William Blair Investment Management LLC now owns 1,058,976 shares of the biotechnology company’s stock worth $43,884,000 after buying an additional 352,045 shares in the last quarter. PointState Capital LP acquired a new position in shares of Repligen Corporation during the second quarter worth $11,984,000. Finally, Norges Bank acquired a new position in shares of Repligen Corporation during the fourth quarter worth $8,527,000. 99.49% of the stock is owned by institutional investors and hedge funds.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.